Clinical trials
Completed Hypertension, Pulmonary trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
72 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 3 |
| 2004 | 2 |
| 2005 | 6 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 2 |
| 2014 | 8 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 72 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 17 |
| University of Giessen | 6 |
| Heidelberg University | 5 |
| United Therapeutics | 5 |
| GlaxoSmithKline | 4 |
| Actelion | 3 |
| Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2 |
| Competence Network for Congenital Heart Defects | 2 |
| Eli Lilly and Company | 2 |
| Insmed Incorporated | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension, Pulmonary | 72 |
| Pulmonary Arterial Hypertension | 26 |
| Heart Failure | 7 |
| Familial Primary Pulmonary Hypertension | 4 |
| Hypertension | 3 |
| Lung Diseases, Interstitial | 3 |
| Pulmonary Disease, Chronic Obstructive | 2 |
| Pulmonary Heart Disease | 2 |
| COVID-19 | 1 |
| Cardio-Renal Syndrome | 1 |
Trials
Showing 1 to 25 of 72. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.